PSNL Stock - Personalis, Inc.
Unlock GoAI Insights for PSNL
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $84.61M | $73.48M | $65.05M | $85.49M | $78.65M |
| Gross Profit | $26.82M | $18.21M | $13.35M | $31.66M | $20.11M |
| Gross Margin | 31.7% | 24.8% | 20.5% | 37.0% | 25.6% |
| Operating Income | $-68,267,000 | $-109,936,000 | $-115,531,000 | $-65,353,000 | $-42,146,000 |
| Net Income | $-81,284,000 | $-108,296,000 | $-113,315,000 | $-65,226,000 | $-41,280,000 |
| Net Margin | -96.1% | -147.4% | -174.2% | -76.3% | -52.5% |
| EPS | $-1.37 | $-2.25 | $-2.48 | $-1.49 | $-1.20 |
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.
Visit WebsiteEarnings History & Surprises
PSNLEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $-0.31 | — | — | — |
Q4 2025 | Nov 4, 2025 | $-0.28 | $-0.24 | +14.3% | ✓ BEAT |
Q3 2025 | Aug 5, 2025 | $-0.25 | $-0.23 | +8.0% | ✓ BEAT |
Q2 2025 | May 6, 2025 | $-0.23 | $-0.18 | +21.7% | ✓ BEAT |
Q1 2025 | Feb 27, 2025 | $-0.32 | $-0.23 | +28.1% | ✓ BEAT |
Q4 2024 | Nov 6, 2024 | $-0.33 | $-0.64 | -93.9% | ✗ MISS |
Q3 2024 | Aug 7, 2024 | $-0.34 | $-0.24 | +29.4% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $-0.44 | $-0.26 | +40.9% | ✓ BEAT |
Q1 2024 | Feb 28, 2024 | $-0.53 | $-0.46 | +13.2% | ✓ BEAT |
Q4 2023 | Nov 7, 2023 | $-0.54 | $-0.51 | +5.6% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-0.56 | $-0.50 | +10.7% | ✓ BEAT |
Q2 2023 | May 3, 2023 | $-0.62 | $-0.61 | +1.6% | ✓ BEAT |
Q1 2023 | Feb 23, 2023 | $-0.65 | $-0.67 | -3.1% | ✗ MISS |
Q4 2022 | Nov 2, 2022 | $-0.63 | $-0.58 | +7.9% | ✓ BEAT |
Q3 2022 | Aug 3, 2022 | $-0.63 | $-0.60 | +4.8% | ✓ BEAT |
Q2 2022 | May 4, 2022 | $-0.57 | $-0.63 | -10.5% | ✗ MISS |
Q1 2022 | Feb 24, 2022 | $-0.51 | $-0.45 | +11.8% | ✓ BEAT |
Q4 2021 | Nov 4, 2021 | $-0.40 | $-0.40 | 0.0% | = MET |
Q3 2021 | Aug 4, 2021 | $-0.39 | $-0.34 | +12.8% | ✓ BEAT |
Latest News
Frequently Asked Questions about PSNL
What is PSNL's current stock price?
What is the analyst price target for PSNL?
What sector is Personalis, Inc. in?
What is PSNL's market cap?
Does PSNL pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to PSNL for comparison